The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
Open accessAbstract
Background The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Methods Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m 2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with ClinicalTrials.gov, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Findings Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.Interpretation These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Funding Bayer and Loxo Oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, entrectinib and lartotrectinib have demonstrated activity in patients with solid tumors with NTRK fusion”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“In this trial, 8 of 159 patients had colon cancer”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“with a median duration of 3.7 months.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“4 patients with colon cancer had a response to therapy”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“and the FDA has approved their use for these patients.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Two therapies, larotrectinib and entrectinib, are FDA-approved for use in CRC with NTRK mutation.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
In the citing paper
“Based on the efficacy across tumor types, larotrectinib was FDA-approved for tumors with NTRK fusions, including CRC.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [85]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationAlectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. E. D. C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,521
Self-citationSkálová, A., Vaněček, T., Šíma, R., Laco, J., Weinreb, I., Perez‐Ordoñez, B., Stárek, I., Geierová, M., Simpson, R. H., Passador‐Santos, F., et al. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d9efcc · Cited by 1,017
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
Tognon, C. E., Knezevich, S. R., Huntsman, D. D., Roskelley, C. D., Melnyk, N., Mathers, J. A., Becker, L. E., Carneiro, F., Macpherson, N. A., Horsman, D. E., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00180-0 · Cited by 908
Drilon, A. E. D. C., Siena, S., Ou, S. I., Patel, M. R., Ahn, M., Lee, J., Bauer, T. M., Farago, A. F., Wheler, J. J., Liu, S. V., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1237 · Cited by 833
Self-citation
Research works printed but not linked: 1
- Geoerger, 2019, Larotrectinib efficacyand safety in pediatric patients with TRK fusion cancer, Pediatr Blood Cancer, 66, S4
Cited by
Sorted by citations
Items 601–700 of 1,000
Martinez‐García, M., Servitja, S., Quintela, N. V., Fernández, A. A., Jaime, A. B., de Ibargüen, B. C. S., Barco, S. D., Campelo, R. G., Sarrió, R. G., & Sepúlveda-Sánchez, J. M. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02803-0 · Cited by 6
Telisnor, G., DeRemer, D. L., Frimpong, E., Agyare, E., Allen, J. M., Ricks‐Santi, L. J., Han, B., George, T. J., & Rogers, S. C. (2023) · Journal of the National Medical Association · doi:10.1016/j.jnma.2023.01.008 · Cited by 6
Long, G., Wang, D., Tang, J., & Tang, W. (2023) · Aging · doi:10.18632/aging.204928 · Cited by 6
Qi, C., Zhou, T., Bai, Y., Chen, H., Yuan, J., Zhao, F., Liu, C. X., Ma, M., Bei, T., Chen, S., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34522 · Cited by 6
Hanai, N., Ando, M., Ishiki, H., Ueda, N., Okano, S., Okamoto, I., Ozawa, H., Kano, S., Kanda, T., Saito, Y., et al. (2025) · Auris Nasus Larynx · doi:10.1016/j.anl.2025.09.004 · Cited by 6
Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib
Sahni, S., Rastogi, S., Yadav, R., & Barwad, A. W. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1575 · Cited by 5
Recent Advancements and Innovations in Pediatric Precision Oncology
Mangum, R., Lin, F. Y. H., & Parsons, D. W. (2024) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002871 · Cited by 5
Schilddrüsenkarzinome – Rolle internistischer Systemtherapien
Brandenburg, T., & Kroiß, M. (2024) · Die Innere Medizin · doi:10.1007/s00108-024-01728-w · Cited by 5
Rubinstein, M., Hong, M. L., Nanda, R. K., Jones, D. T., Aboaid, H., Myat, Y. M., & Thein, K. Z. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.067791 · Cited by 5
Molecular Pathogenesis of Uterine Sarcomas: Mechanisms and Implications for Treatment
Chiang, S. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023434 · Cited by 5
Integrated bioinformatics analysis of differences between EAC and ESCC
Lyu, Q., Chai, Y., Chen, W., Chen, Y., & Li, Y. (2025) · BMC Cancer · doi:10.1186/s12885-025-15090-z · Cited by 5
Xu, M., Zheng, Y., Zhao, L., Wang, S., Chen, J., Fu, Z., Ma, A., Liang, B., Huang, Y., Xu, H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02649-w · Cited by 5
Hirano, H., Naito, Y., Takahashi, T., Hirota, S., Kim, K.-M., Ryu, M., Wang, J., Cao, H., Li, J., Li, C.-F., et al. (2026) · Gastric Cancer · doi:10.1007/s10120-026-01773-4 · Cited by 5
New Drug Approvals for Sarcoma in the Last 5 Years
Thirasastr, P., Brahmi, M., Dufresne, A., Somaiah, N., & Blay, J. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2022.03.003 · Cited by 5
Lin, R., Li, Y., Lin, Y., Tian, W., Jiang, L., & Li, J. (2023) · Diagnostic Cytopathology · doi:10.1002/dc.25143 · Cited by 5
Fukushima, T., Goto, K., Hayashi, T., Ikeda, K., Hatayama, T., Yamanaka, R., Iwane, K., Tasaka, R., Kohada, Y., Takemoto, K., et al. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad148 · Cited by 5
Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?
Perri, F., Fusco, R., Sabbatino, F., Fasano, M., Ottaiano, A., Cascella, M., Marciano, M. L., Pontone, M., Salzano, G., Maiello, M. E., et al. (2024) · Cancers · doi:10.3390/cancers16050970 · Cited by 5
Cheng, L., & Newbold, K. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-38605-3_19 · Cited by 5
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2
Kikuchi, Y., Shimada, H., Yamasaki, F., Yamashita, T., Araki, K., Horimoto, K., Yajima, S., Yashiro, M., Yokoi, K., Cho, H., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02497-0 · Cited by 5
Willis, C., Au, T. H., Hejazi, A. A., Griswold, C. R., Schabath, M. B., Thompson, J., Malhotra, J. D., Federman, N. C., Ko, G., Appukkuttan, S., et al. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.7.672 · Cited by 5
Self-citationHou, S., Cheng, C.-Y., Chen, W., Chang, E.-M., & Lin, C. (2025) · Life · doi:10.3390/life15010099 · Cited by 5
Cutting-edge technologies illuminate the neural landscape of cancer: Insights into tumor development
Wang, Y., Wang, Z., Mao, X., Zhang, H., Zhang, L., Yang, Y., Liu, B., Li, X., Luo, F., & Sun, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217667 · Cited by 5
Nicolini, A., Ferrari, P., Silvestri, R., & Bini, D. A. (2025) · MedComm · doi:10.1002/mco2.70373 · Cited by 5
Linos, K. D., Kerr, D. A., Sümegi, J., & Bridge, J. A. (2020) · Journal of Cutaneous Pathology · doi:10.1111/cup.13915 · Cited by 5
The evolving paradigm of precision medicine in lung cancer
Passiglia, F., & Scagliotti, G. V. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000778 · Cited by 5
Systemic Therapy in Thyroid Cancer
Agrawal, A., Noronha, V., Patil, V., Menon, N. N., Kapoor, A., Chougule, A., Chandrani, P., & Prabhash, K. (2021) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-021-01398-2 · Cited by 5
Looking Beyond the Glioblastoma Mask: Is Genomics the Right Path?
Montella, L., Gaudio, N. D., Bove, G., Cuomo, M., Buonaiuto, M., Costabile, D., Visconti, R., Facchini, G., Altucci, L., Chiariotti, L., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926967 · Cited by 5
Targeted Therapy for Melanomas Without BRAF V600 Mutation
Choi, J. S., & Chandra, S. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01306-z · Cited by 5
Immunotherapy approaches for rare pediatric solid tumors: advances and future directions
Pineda, J. C. F., Wedekind, M. F., & Glod, J. W. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001206 · Cited by 5
Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma
Baranov, E., & Nowak, J. A. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.05.002 · Cited by 5
Duan, S., Dong, L., Wang, B., Wei, S., Gong, X., Yu, P., Li, C., Gao, Y., Ye, L., Wang, H., et al. (2021) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2021.104886 · Cited by 5
Christofyllakis, K., Monteiro, A. R., Cetin, O., Kos, I. A., Greystoke, A., & Luciani, A. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.04.013 · Cited by 5
Treatment of biliary tract carcinoma over the last 30 years
Midorikawa, Y. (2022) · BioScience Trends · doi:10.5582/bst.2022.01267 · Cited by 5
New Drug Development and Clinical Trial Design by Applying Genomic Information Management
Ko, Y. K., & Gim, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081539 · Cited by 5
Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update
Iliev, P., Jaworski, C., Wängler, C., Wängler, B., Page, B. D. G., Schirrmacher, R., & Bailey, J. J. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2358818 · Cited by 5
Progressive metastatic infantile fibrosarcoma with multiple acquired mutationsPreprint
Furtado, L. V., Kacar, M., Mostafavi, R. M., Shi, Z., Ruiz, R., Koo, S. C., Santiago, T., Segers, B., Krasin, M. J., Abramson, Z. R., et al. (2023) · Molecular Case Studies · doi:10.1101/mcs.a006277 · Cited by 5
Self-citationClinicopathologic characterization of secretory carcinoma of salivary gland
Han, F., Liu, F., Wang, H., Qin, Y., Lü, Q., Wu, X., Guo, Z., & Nan, X. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03561-9 · Cited by 4
Takano, G., Kawakita, D., Iwata, H., Hattori, Y., Nakajima, K., Tsuzuki, Y., Sudo, S., Toshito, T., Hayashi, K., Matoba, T., et al. (2025) · Head & Neck · doi:10.1002/hed.28149 · Cited by 4
Brose, M. S., Westphalen, C. B., Pan, X., Bernard‐Gauthier, V., Kurtinecz, M., Guo, H., Aris, V. M., Brett, N. R., Majdi, A., Subbiah, V., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00500 · Cited by 4
Self-citationPediatric Cancer Genetics and Genomics
Mardis, E. R. (2025) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120823-010156 · Cited by 4
Jansen, L., Nachtsheim, L., Wolber, P., Shabli, S., Eßer, J., Quaas, A., Morris, L. G. T., Ho, A. L., Klußmann, J. P., Arolt, C., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251357727 · Cited by 4
Systemic Therapy for Advanced Thyroid Cancer—New Personalized Options
Cheng, L., & Newbold, K. L. (2025) · Drugs · doi:10.1007/s40265-025-02233-6 · Cited by 4
NGF/BDNF–Trk/p75NTR signaling in osteosarcoma immunity: biomarkers and therapeutic opportunities
An, L. K., Zhuang, Y., & Sun, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719012 · Cited by 4
Akhave, N. S., Song, Z., Hong, D. S., Gray, R. J., Wang, V., McShane, L. M., Rubinstein, L., Patton, D. R., Williams, P. M., Hamilton, S. R., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00612 · Cited by 4
Self-citationTreating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here
May, M. S., Park, W., & O'Reilly, E. M. (2026) · Drugs · doi:10.1007/s40265-026-02295-0 · Cited by 4
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors
Kato, S., Adashek, J. J., Subbiah, V., Fu, S., Sun, M., Nguyen, L. M., Brown, E. J., Yap, T. A., Karp, D. D., Piha-Paul, S. A., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01153-y · Cited by 4
Self-citationKönig, D., & Rothschild, S. I. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.019 · Cited by 4
Pediatric Sarcomas: The Next Generation of Molecular Studies
Giannikopoulos, P., & Parham, D. M. (2022) · Cancers · doi:10.3390/cancers14102515 · Cited by 4
Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy
Zhao, Y., & Long, Y. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2085964 · Cited by 4
Kelner, M., da Silva, B. C., Montella, T. C., Aguiar, P. N., Lopes, G. D. L., Jr., Ferreira, C. G., & Marchi, P. D. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2022.08.004 · Cited by 4
Desai, A. P., Xiao, A. H., Choi, D., Toruner, M. D., Walden, D. M., Halfdanarson, T. R., Alberts, S. R., McWilliams, R. R., Mahipal, A., Ahn, D. H., et al. (2024) · Cancers · doi:10.3390/cancers16101861 · Cited by 4
A Revisit on FDA Approved Anticancer Drugs (1949 – 2024)
Myla, L. S., & Gope, E. R. (2024) · Journal of Pharma Insights and Research. · doi:10.69613/k20qe441 · Cited by 4
Deland, L., Keane, S., Bontell, T. O., Bexelius, T. S., Gudinavičienė, I., Cuesta, E. A. D. L., Luca, F. D., Nilsson, J. A., Carén, H., Mörse, H., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae254 · Cited by 4
Podder, V., Bellur, S. S., Margolin, K. A., Advani, P. P., Mahtani, R. L., Subbiah, V., Novo, G. B., Ranjan, T., & Ahluwalia, M. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01593-8 · Cited by 4
Zeng, S., Jiang, K., Ge, J., Tang, M., Wen, Y., Ma, X., Liu, H., & Xiong, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-13271-w · Cited by 4
Arter, Z., Lee, A. T., Nagasaka, M., & Ou, S. I. (2025) · Cancer Medicine · doi:10.1002/cam4.70665 · Cited by 4
Molecular oncology of iodine refractory thyroid cancer current therapies and perspective
Cherifi, F., & Awada, A. H. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104679 · Cited by 4
Oncogenic mutations of clinical significance in colorectal cancer
Lea, V., Lim, S. H.-S., & Lee, C. S. (2025) · Pathology · doi:10.1016/j.pathol.2025.05.001 · Cited by 4
Advances in Hereditary Colorectal Cancer: How Precision Medicine Is Changing the Game
Lin, S., Zhou, C., Chen, H., Zhou, X., Yang, H., Sun, L., Zhang, L., & Zhang, Y. (2025) · Cancers · doi:10.3390/cancers17213461 · Cited by 4
Personalized Medicine in Oncology
Vanderwalde, A. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2820-5 · Cited by 4
Targeted Therapy for Non–Small Cell Lung Cancer
Brea, E. J., & Rotow, J. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.009 · Cited by 4
Kumarasinghe, P. M., Houghton, D., Allanson, B. M., & Price, T. J. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.05.004 · Cited by 4
The Diverse Roles of ETV6 Alterations in B-Lymphoblastic Leukemia and Other Hematopoietic Cancers
Monovich, A. C., Gurumurthy, A., & Ryan, R. J. H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_13 · Cited by 4
Current Landscape of NTRK Inhibition for Pediatric CNS Tumors
Moreira, D. C., Mikkelsen, M. K., & Robinson, G. W. (2024) · CNS Drugs · doi:10.1007/s40263-024-01121-z · Cited by 4
Advances in target drugs and immunotherapy for biliary tract cancer
Deiana, C., Ricci, C., Vahabi, M., Ali, M., Brandi, G., & Giovannetti, E. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2416230 · Cited by 4
Lee, C. L., Saborowski, A. L., & Vogel, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2432488 · Cited by 4
Molecular features and clinical actionability of gene fusions in colorectal cancer
Sullo, F. G., Garinet, S., Blons, H., Taïeb, J., Laurent‐Puig, P., & Gallois, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104656 · Cited by 4
Houmsse, M. M., Muskara, A., Pasca, D., Roy, A., Sughra, S., Ghazi, S. M., Addison, D., & Husain, M. (2025) · Cancers · doi:10.3390/cancers17050827 · Cited by 4
Diagnosis and management of brain metastasis from thyroid cancer
Cascio, V. M., Doerfler, W. R., & Taneja, C. (2025) · Endocrine Oncology · doi:10.1530/eo-25-0002 · Cited by 4
Leone, G., Passiglia, F., Bironzo, P., Bertaglia, V., & Novello, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-710 · Cited by 4
Analysis of pemetrexed-based chemotherapy in the treatment of advanced colorectal cancer
Yu, Z., Wang, J., Cai, X., Gao, Z., Wang, S., & Gu, Y. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1095 · Cited by 4
Refractory infantile high‐grade glioma containing TRK‐fusion responds to larotrectinib
Waters, T. W., Moore, S. A., Satō, Y., Dlouhy, B. J., & Sato, M. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28868 · Cited by 4
Pircher, M., Briner, H. R., Bonomo, M., Horcic, M., Petrausch, U., Helbling, D., & Winder, T. L. (2021) · Medicine · doi:10.1097/md.0000000000024463 · Cited by 4
Bueno, F., Abelleira, E., von Stecher, F., de Lima, A. P., & Pitoia, F. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000325 · Cited by 4
Ivanov, N. S., Панферова, А. В., Коновалов, Д. М., Teleshova, M. V., Bolshakov, N. A., Shamanskaya, T. V., Druy, A. E., & Kachanov, D. Y. (2022) · Pediatric Hematology/Oncology and Immunopathology · doi:10.24287/1726-1708-2022-21-1-110-120 · Cited by 4
Mfumbilwa, Z. A., Wilschut, J. A., Simons, M., Ramaekers, B. L. T., Joore, M. A., Retèl, V. P., der Welle, C. M. C., Schramel, F. M. N. H., van de Garde, E. M. W., & Coupé, V. M. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-29286-5 · Cited by 4
Best Achievements in Clinical Thyroidology in 2020
Lee, E. K., & Park, Y. J. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.103 · Cited by 4
Πασπάλα, Ά., Bompetsi, G., Paschou, S. Α., Charalambopoulos, A., Pikoulis, E., Peppa, Μ., & Nastos, C. (2024) · HORMONES · doi:10.1007/s42000-024-00597-0 · Cited by 3
Kitadai, R., Okuma, Y., Shibata, T., Kohno, T., & Koyama, T. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115380 · Cited by 3
BTNL9 exerts anti-cancer effects by inhibiting CDC20 to induce G2/M arrest in pancreatic cancer
Xiao, M., Luo, Z., Yu, A.-R., Xu, K., & Zhou, W. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.108274 · Cited by 3
Updates on molecular targets and clinical trials with targeted therapies for pancreatic cancer
Safyan, R. A., & Chiorean, E. G. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102268 · Cited by 3
Camidge, D. R., Phillips, W. J., Nemenoff, R. A., & Cittelly, D. M. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.12.104 · Cited by 3
Multidimensional effects of genetic mechanisms in cancer occurrence, development and treatment
Wang, X., Shi, X., Liao, S., Su, T., Gu, Y., Zhang, H., & Li, Z. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.03.006 · Cited by 3
Disarming the “Neural Hijack”: Repurposing neuroactive drugs for cancer therapy
Jin, M.-Z., Dang, H.-R., & Jin, W.-L. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109051 · Cited by 3
What’s New in Pediatric Orthopaedic Tumor Surgery
Williams, A. K., Crawford, B., Federman, N. C., Bernthal, N. M., & Arkader, A. (2020) · Journal of Pediatric Orthopaedics · doi:10.1097/bpo.0000000000001689 · Cited by 3
Self-citationGemcitabine Maintenance Therapy in Patients With Metastasized Soft Tissue Sarcomas
Harrer, D. C., Buschauer, S., Sterz, U., Menhart, K., Wendl, C. M., Heudobler, D., Grube, M., Pukrop, T., Herr, W., & Vogelhuber, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.755439 · Cited by 3
Kim, M., Hong, K. T., Park, H. J., Kim, B. K., Lee, Y. J., Choi, J. Y., Choi, Y. H., Park, S., Kim, H., & Kang, H. J. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30679 · Cited by 3
Molecular Alterations in Pediatric Solid Tumors
Slack, J. C., & Church, A. J. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.012 · Cited by 3
Pan-Cancer Molecular Biomarkers
Dong, F. (2024) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2023.08.013 · Cited by 3
Sinichenkova, K. Y., Sidorov, I., Kriventsova, N. A., Коновалов, Д. М., Abasov, R. K., Usman, N., Karachunskiy, A. I., Novichkova, G. A., Литвинов, Д. В., & Druy, A. E. (2024) · Oncotarget · doi:10.18632/oncotarget.28606 · Cited by 3
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Doi, T., Ishikawa, T., Moriguchi, M., & Itoh, Y. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf012 · Cited by 3
Targeted therapy for pediatric glioma: RAF(t)ing in the molecular era
Shen, Z.-P., Zhang, Z., Li, N., Xu, L., & Chen, Y. (2025) · World Journal of Pediatrics · doi:10.1007/s12519-025-00889-4 · Cited by 3
Du, S., Hu, Z., Shen, J., Hamuro, L., Lam, J. L., Lu, M., Zhu, L., Roy, A., & Kondic, A. G. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70036 · Cited by 3
Ghossein, R. A., Instrum, R. S., Doğan, S., Chongtham, N., Mullaney, K. A., Roy, D., Shaha, A., Tuttle, R. M., Ganly, I., Morris, L. G. T., et al. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04133-2 · Cited by 3
Consenso multidisciplinar para optimizar la determinación de alteraciones del gen NTRK
Rojo, F., Colomer, R., López‐Ríos, F., Bautista, F. J., Alvarez, R. M., de Álava, E., Hladun, R., & Garrido, P. (2021) · Revista Española de Patología · doi:10.1016/j.patol.2021.05.003 · Cited by 3
Cho, M. T., Beechinor, R. J., Gholami, S., & Grothey, A. F. (2021) · Current Colorectal Cancer Reports · doi:10.1007/s11888-021-00466-7 · Cited by 3
Construction of an α-chiral pyrrolidine library with a rapid and scalable continuous flow protocol
Shan, C., Cao, L., Yang, J., Cheng, R., Yao, X., Liang, C., Sun, M., & Ye, J. (2022) · Reaction Chemistry & Engineering · doi:10.1039/d2re00145d · Cited by 3
New hope for patients with BRAF V600E-mutant anaplastic thyroid cancer: lights and shadows
Grani, G., Filetti, S., & Durante, C. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-603 · Cited by 3
Basté, N. (2022) · Cancer Medicine · doi:10.1002/cam4.5106 · Cited by 3
Second line drug therapy for biliary cancer
Вячеславович, С. И., Breder, V. V., Stilidi, I. S., Лактионов, К. К., Кудашкин, Н. Е., Егорова, А. В., & Чулкова, С. В. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2022-16-22-136-147 · Cited by 3
Metadata
- Authors
- Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., & Drilon, A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Stanford Medicine (US)
- Massachusetts General Hospital (US)
- Seattle Children's Hospital (US)
- University of Copenhagen (DK)
- Vanderbilt University Medical Center (US)
- University of California, Los Angeles (US)
- University of Southern California (US)
- Université Paris-Saclay (FR)
- University Hospitals Cleveland Medical Center (US)
- St. Jude Children's Research Hospital (US)
- Olgahospital (DE)
- Université Paris Descartes (FR)
- Cancer Trials Ireland (IE)
- University of Chicago (US)
- Thomas Jefferson University (US)
- National Cancer Center Hospital East (JP)
- German Cancer Research Center (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Bayer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Drilon, Alexander
- ORCID
- Hong, David S
- DuBois, Steven G
- Kummar, Shivaani
- Farago, Anna F
- Albert, Catherine M
- Rohrberg, Kristoffer S
- Nagasubramanian, Ramamoorthy
- Berlin, Jordan D
- Federman, Noah
- Mascarenhas, Leo
- Geoerger, Birgit
- Dowlati, Afshin
- Pappo, Alberto S
- Bielack, Stefan
- Doz, François
- McDermott, Ray
- Patel, Jyoti D
- Tahara, Makoto
- Pfister, Stefan M
- Witt, Olaf
- Ladanyi, Marc
- Rudzinski, Erin R
- Nanda, Shivani
- Childs, Barrett H
- Laetsch, Theodore W
- Hyman, David M
- Drilon, Alexander
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 21
- Issue
- 4
- Pages
- 531-540
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7497841
- OpenAlex
- W3008107700
- Cited by
- 1,028
- References
- 25
- Citations by year
- 2026: 106 · 2025: 148 · 2024: 162 · 2023: 178 · 2022: 202 · 2021: 171 · 2020: 60
- FWCI
- 86.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Loxo Oncology
- Bayer Corporation
- Bayer Fund
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- larotrectinib, TRK inhibitors, objective response rate, long-term safety, adverse events, childhood cancer, adult cancer, metastatic cancer, pooled analysis of clinical trials, alanine aminotransferase elevation, neutropenia, anemia, complete response, dose-limiting toxicity
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasms, Proteins, Pyrazoles, Pyrimidines, Vesicular Transport Proteins, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
